Skip to content

IEMbase 0674: PMVK-related phosphomevalonate kinase deficiency

Scope

Field Value
IEMbase ID 674
Nosology 14.7.03.01
Nosology code IEM0742
Gene PMVK
External IDs OMIM:175800; ORPHA:735
Generated mapping UNMAPPED; best candidate Mevalonate_Kinase_Deficiency.yaml
Candidate DisMech targets Broad mevalonate-pathway context only; no exact PMVK/POROK1 target
Review date 2026-07-07

IEMbase phenotype signal

IEMbase represents autosomal dominant PMVK-related phosphomevalonate kinase deficiency, labeled porokeratosis type 1 and porokeratosis of Mibelli.

The cached phenotype signal is dermatologic only: actinic porokeratosis and keratotic skin lesions in adolescence and adulthood. There are no biochemical rows in the cached record.

DisMech phenotype coverage

No exact PMVK, phosphomevalonate kinase deficiency, porokeratosis type 1, or porokeratosis of Mibelli target was identified.

Mevalonate_Kinase_Deficiency.yaml is a biologically adjacent but incorrect target. It models autosomal recessive MVK-related systemic autoinflammation across the HIDS/mevalonic-aciduria spectrum, with recurrent fever, elevated mevalonic acid, inflammasome activation, and neurologic features in severe disease. It does not model autosomal dominant PMVK-associated porokeratosis.

RNU12-related_Minor_Spliceopathy.yaml includes porokeratosis as part of CDAGS syndrome, but that is an unrelated congenital spliceopathy context rather than PMVK disease coverage.

Concordance and completeness

Judgement: true local gap. The generated mevalonate-kinase candidate is understandable as a pathway-neighbor match, but it would import the wrong gene, inheritance pattern, and systemic phenotype.

The IEMbase row is narrow, so the key preservation point is the adolescent/adult actinic porokeratosis and keratotic-lesion dermatologic presentation rather than classic mevalonate kinase deficiency features.

Curation actions

  • Add a dedicated PMVK/POROK1 target if this disease is curated.
  • Do not map this record to MVK-related mevalonate kinase deficiency.
  • Treat RNU12/CDAGS porokeratosis as unrelated differential context only.
  • Preserve actinic porokeratosis and keratotic skin lesions as the core phenotype prompts.